BROOKS LABORATORIES Share Price

Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others. As of 25 May 2026, BROOKS LABORATORIES share price is ₹56.41. The stock opened at ₹54.89, compared to its previous close of ₹53.73. During today's trading session, BROOKS LABORATORIES share price moved in the range of ₹54.54 to ₹56.41, with an average price of ₹55.47 for the day. Looking at its last 52-week, the stock has touched a low of ₹54.54 and a high of ₹56.41. On the performance front, BROOKS LABORATORIES share price has declined by 47.50% over the last six months and is down 60.17% on a year-on-year basis.

The market capitalization of BROOKS LABORATORIES is ₹159 Crs, with a P/E ratio of 7.4 and a dividend yield of 0.00%.